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Abstract The aim of the study was to assess the rate, pat-
tern, and time of recurrence in patients with triple-negative
breast cancer (TNBC) and to evaluate factors influencing
recurrence and overall survival in this group of patients. Out
of 2,534 consecutive breast cancer patients diagnosed
between January 2005 and December 2006, 228 (9 %) were
TNBC (ER/PR/HER2-negative). The clinicopathological
characteristics were determined using descriptive statistics.
The overall survival (OS) and disease-free survival
(DFS) were calculated using the Kaplan–Meier method. The
univariate and multivariate analyses were developed to
identify factors influencing recurrence and survival in TNBC
patients. After 6 years of observation, metastatic disease
occurred in 35 % of all TNBC patients: 15 % in the brain,
14 % in the lungs, 11 % in the bones, 8 % in the liver, and
14 % had locoregional relapse. The highest risk of recur-
rence was during the first 3 years after primary treatment,
and then, during the next 2 years of observation, it did not
change. 6-year DFS and OS were 68 and 62 %, respectively.
Factors influencing recurrence were tumor size and systemic
adjuvant chemotherapy, while factors influencing overall
survival were tumor size, nodal status, adjuvant/neoadjuvant
treatment, and metastases in the brain, liver, and bones.
Characteristic pattern of recurrence in time was revealed.
The tumor size was responsible for recurrence despite lack of
involvement of lymph nodes. Aggressive adjuvant/neoad-
juvant treatment ordered in all clinical stages of TNBC
(including N0) was factor responsible for avoiding local and
distant relapse and prolonging overall survival.
Keywords Brain metastases  Metastatic breast cancer 
Prognostic factor  Recurrence pattern  Triple-negative
breast cancer  Tumor size
Introduction
According to ASCO guideline and the latest St Gallen con-
sensus, triple-negative breast cancer (TNBC) occurs only if
there is no expression of estrogen receptor (ER-negative),
progesterone receptor (PR-negative), and there is neither
expression nor amplification of human epidermal growth
factor receptor 2 (HER2-negative) in a tumor [1, 2]. Apart
from these clinicopatological markers and classical classi-
fication of breast cancer subtypes, there are molecular gene
tests, which allow dividing TNBC into two main subtypes—
more common basal-like and claudin-low [3]. Still, molec-
ular classification has still no influence over clinical
management. TNBC accounts for about 9–21 % of all breast
cancers including patients with stage I–IV breast cancer
[4–8]. In the past, this rate was higher because it included
cases with ER/PR less than 10 %.
TNBC patients have poorer outcomes compared with
other cancer subtypes [7–14]. They are at higher risk of
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early recurrence, mainly in the lungs, brain, and soft tissue
[4, 6, 13–18]. The highest risk of relapse is between the
first and third year after primary treatment. In cases of
recurrence, the survival is shorter than in non-TNBC
patients [9, 13, 14, 19, 20]. However, TNBC is more sen-
sitive to chemotherapy. The rate of pathological complete
remission (pCR) after neoadjuvant chemotherapy is higher
than in other breast cancer subtypes [11, 13, 19]. On the
other hand, methods of the treatment in this group of
patients are still limited in clinical practice because of the
lack of molecular targets. The adjuvant treatment is usually
recommended in TNBC and should include anthracyclines,
taxanes, and an alkylating agent [2, 21].
The aim of this study was to analyze recurrence pattern
in order to determine the prognostic factors of recurrence
and overall survival in a group of consecutive 228 TNBC
patients treated at Cancer Center and Institute of Oncology
in Warsaw, Poland, between the years 2005 and 2006.
Patients and methods
Patients
Medical records of 2,534 consecutive patients with newly
diagnosed breast cancer between January 2005 and
December 2006 were reviewed. We decided to analyze this
group of patients because of similar management, and the
fact that most of recurrence in TNBC patients occurs in the
first 5 years after primary treatment. There were 228 TNBC
patients (9 % out of all breast cancers) according to the
latest recommendations [1, 2], therefore, without expression
of ER, PR, and HER2 receptors. We excluded 23 patients
who were in the past also classified as TNBC (with
expression of ER/PR receptors less than 10 %). The status
of ER, PR, and HER2 was determined based on the biopsy
of primary tumor. Staining was performed using primary
antibodies against ER (Clone 6F11, Novocastra), PR (Clone
16, Novocastra), and HER2 (Polyclonal HercepTest,
DAKO). If HER2 was 2? by immunohistochemistry (IHC),
fluorescence in situ hybridization (FISH; HER2 DNA Probe
Kit, Vysis) was performed additionally, and if the result was
only negative, patients were included to our analysis.
Patients were observed until October 2011.
Statistical method
The clinicopathological characteristics were determined
using descriptive statistics.
Disease-free survival was defined as the time from
diagnosis of TNBC to first locoregional or distant recur-
rence. Overall survival was the time from TNBC diagnosis
to death. DFS and OS curves were calculated using the
Kaplan–Meier method. Recurrence rates were presented by
cumulative hazard rates and annual hazard rates. A p value
\0.05 was considered significant.
The univariate and multivariate analyses were devel-
oped to identify factors influencing recurrence and overall
survival in TNBC patients. The following factors were
analyzed in Cox model: age at diagnosis (\55 vs. C50),
primary tumor extension (T2 vs. T1; T3 vs. T1; T4 vs. T1),
lymph node involvement (N1 vs. N0; N2 vs. N0; N3 vs.
N0), histological cancer type (ductal vs. lobular; ductal vs.
medullar, apocrinal, papillary), result of HER2 in IHC
staining (HER2 1? vs. HER2 2?), adjuvant/neoadjuvant
chemotherapy (yes vs. no).
Results
Patients
The median age of patients at diagnosis was 54.5 years
(range 24–86) (Table 1). Majority of patients were diag-
nosed with stage II or III breast cancer (47 and 34 %,
respectively), and only 9 patients (4 %) had an evidence of
metastases at initial diagnosis. 126 patients (55 %) had
positive axillary lymph nodes at presentation. The most
common histological type was ductal cancer (81 %). 71
patients (31 %) were treated with neoadjuvant chemo-
therapy due to locally advanced breast cancer—almost half
of them with 4 cycles AT (doxorubicin plus docetaxel)
followed by 4 cycles of CMF (cyclophosphamide plus
methotrexate plus fluorouracil)—and two-thirds of these
patients received the taxane-containing regimens. Of note,
pCR rate in all types of neoadjuvant chemotherapy was
only 9.9 % (7 patients). There was no difference in overall
survival regardless of the type of neoadjuvant chemother-
apy given. 90 % of patients received surgery, and in this
group, mastectomy was the most common type of surgery
(85 %). The rate of breast-conserving surgery was only
15 % because many patients had stage III cancer. Almost
half of all patients received adjuvant chemotherapy—AC
(doxorubicin plus cyclophosphamide) was the most com-
mon regimen; taxanes were used only in 12 % of patients
in this group.
One-third of patients with metastatic disease did not
receive systemic therapy, mainly due to their poor func-
tional status. First-, second-, and third-line chemotherapy
were used in 23 patients (29 % of all patients with
metastases), 18 patients (23 %), and 12 patients (15 %),
respectively. A few patients received hormonal therapy—
only in cases, where ER/PR conversion occurred in
metastases. Bevacizumab was used in 9 patients, only in
addition to first-line chemotherapy (in 1 case, bevacizumab
was continued with second-line chemotherapy). One
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patient received trastuzumab in metastatic setting because
HER2 conversion occurred.
Recurrence
During the 6 years of observation, the metastatic disease
occurred in one-third of all TNBC patients (including these
9 patients initially with stage IV disease): 15 % in the brain,
14 % in the lungs, 11 % in the bones, 8 % in the liver, and
14 % patients had locoregional relapse (Table 1)—majority
of these patients had metastases in different sites. The most
common site of the first recurrence was lungs. Interestingly,
Table 1 Characteristics of 228 triple-negative breast cancer patients
Patient and tumor characteristics No. of
patients
%
Age at initial diagnosis, years 54.5
Median
Range 24–86






Ductal invasive 153 81
Lobular invasive 13 7
Medullar, apocrinal, papillary, mucinous,
planoepitheliale, neuroendocrine invasive
23 12






Type of neoadjuvant chemotherapy—regimens
AT ? CMF 32/71 45
AT 15/71 21










Type of adjuvant chemotherapy
AC 79/118 67
CMF 15/118 12.50
A ? T 14/118 12








Site of initial recurrence
Lung 29 13














Locoregional recurrence 31 14
Other 13 6
Systemic therapy after recurrence
Yes 54/79 68
No 25/79 32
Type of systemic therapy after recurrence*
Chemotherapy 53/79 67
Hormonal therapy 7/79 9
Targeted therapy 10/79 13







Type of targeted therapy
Bevacizumab 9/10 90
Trastuzumab 1/10 10






Second breast cancer 5 2
Other primary cancer 12 5
*Some patients received different types of systemic therapy
Med Oncol (2013) 30:388 Page 3 of 8
123
almost half of all brain metastases occurred in patients with
lung involvement—in this group of patients, lung metas-
tases were diagnosed before or concurrently with brain
metastases apart from 1 patient with prior brain disease.
The highest risk of recurrence was during the first
3 years after primary treatment, and then, during the next
2 years of observation, it did not change significantly
(plateau after 3 years; Figs. 1, 2). In the study population,
the risk of local relapse and metastases to the brain and
lungs peaked in second year and then declined signifi-
cantly, whereas the risk of metastases to the liver and bones
was also the highest in the first 2–3 years but then fell
slightly. Furthermore, 5 years after initial diagnosis new
metastases occurred only in bones. However, longer fol-
low-up is needed to complete and verify these results.
Cumulative hazards of metastases are presented in
Fig. 2 and Table 2. The risk of new metastases after
3 years from primary treatment was very low (\1 %/year
in every site).
Survivals
Median DFS and OS were not reached at the time of
analysis, and 6-year DFS and OS were 68 and 62 %,
respectively (Fig. 3). Less than half of all patients experi-
enced recurrence or died, so there was only possibility to
estimate the means of DFS and OS (4.4 and 5 years,
respectively).
88 patients (39 %) died during 6-year observation. In 19
patients, cause of death was not associated with breast
cancer. 12 patients (5 %) developed other primary cancer
(pancreatic cancer, colon cancer, and ovarian cancer—2
cases; lung cancer, melanoma, kidney cancer, endometrial
cancer, cancer of the ampulla of Vater, and skin cancer—1
case) and half of them (6 patients) died; only 2 of these
patients had also metastatic breast cancer, but it did not
cause their death.
The survival after recurrence differed depending on the
site of metastases (Table 3) and was the shortest in the
group of patients with liver metastases (3.5 months). The
longest survival occurred in patients with lungs metastases
and with local relapse (9.8 and 9 months, respectively).
The median survival from the detection of brain metastases
was 6.3 months.
Prognostic factors
Factors influencing disease-free survival
In the univariate analysis, tumor size, nodal status, and
adjuvant/neoadjuvant chemotherapy were found to have
significant impact on DFS. Additionally, there was no
difference in DFS in patients with HER2 1? or 2? in IHC
staining. Patients’ age also did not influence DFS. How-
ever, in the multivariate analysis, only tumor size and
systemic adjuvant chemotherapy were significant for DFS
(Table 4).
Factors influencing overall survival
The same factors for DFS were analyzed as for OS.
Additionally, the development of metastases in different
sites was parsed. Similar results were found—tumor size,
nodal status, and adjuvant/neoadjuvant chemotherapy were
significant in univariate analysis while patients’ age and
HER2 result in IHC (1? vs. 2?) was not. The risk of death
Fig. 1 Risk of recurrence in different sites in triple-negative breast
cancer patients
Fig. 2 Cumulative hazard rates depending on the site of metastases
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was higher in cases with evidence of metastases in every
location. Finally, in multivariate analysis tumor size, nodal
status, adjuvant/neoadjuvant treatment, and metastases to
the brain, liver, and bones were factors influencing OS.
Discussion
The old term for TNBC included tumors with low
expression of hormonal receptors (ER/PR \ 10 %). There
are a lot of publications with data referring to this old
classification making the rate of TNBC tumors to be higher
in the past than nowadays. In our study, this rate was 9 %
and is comparable to other studies (9–21 %) [4–8]. The rate
of TNBC patients was in some studies even higher, but
they assessed other groups of TNBC patients (e.g. African
American patients, only neoadjuvant setting or patients
with stage I–III breast cancer) [12, 13, 22].
The frequency of nodal involvement at diagnosis in
TNBC patients differs in studies with conflicting results.
Lin et al. demonstrated recently that TNBC tumors were
less likely to be lymph node-positive, and a similar out-
come was reported in other studies (positive lymph nodes:
38 and 41 %, respectively) [14, 22]. Contrary, in our study,
55 % of TNBC patients had lymph node involvement,
which is consistent with the frequency of 54.4 % reported
in other study [9]. Nodal status issue remains unresolved.
Neoadjuvant chemotherapy consisting of anthracyclines
and taxanes has been widely accepted as standard therapy
of locally advanced breast cancer [21]. Patients with TNBC
have increased pCR rates compared with non-TNBC. This
rate was 29 % in patients who received neoadjuvant
anthracycline-based chemotherapy and 38 % after anthra-
cycline and taxane combined treatment [11, 19]. In our
study, two-thirds of patients received anthracycline-taxane
neoadjuvant chemotherapy and only 15 % of them
achieved pCR—recurrence occurred in almost half of
patients in this small group. However, such result is
doubtful because there were only 7 patients who achieved
pCR (all of them received chemotherapy containing tax-
anes); the result was lower than normal. In addition, it was
reported that if pCR was achieved, patients with TNBC and
non-TNBC would have similar survival [13, 19].
TNBC has a characteristic pattern of recurrence. Dent
et al. [9] reported that in their study the risk of recurrence
rose sharply from the date of diagnosis, peaked at 1–3 year
interval and then dropped quickly. Similarly, in another
study, the risk of relapse was strongly time-dependent and
dramatically higher for TNBC patients during the first
3 years after diagnosis [13]. The same phenomenon was
observed in our study. Additionally, we determined the
sequence of metastases development in different sites.
Local relapse and metastases to the brain and visceral














Brain 4.3 12 16 17.6
Lungs 3.8 10.7 15.1 15.7
Liver 4.2 6.5 9.1 9.1
Bones 4.3 6.7 8.1 9.4
Local
recurrence
3.9 13.3 13.9 14.6
Fig. 3 a Disease-free survival (DFS) and b overall survival (OS) in
triple-negative breast cancer patients
Table 3 Survival after recurrence depending on the site of
metastases






Brain 34 6.3 4.9–7.7
Lungs 33 9.8 1.7–17.8
Local recurrence 31 9 7.5–10.6
Bones 26 5.5 2.7–8.4
Liver 19 3.5 0–7.7
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organs occurred in the first 3 years, but the risk of bone
metastases declined from diagnosis and then rose slightly
again after 5 years of observation (Fig. 1). The brain and
lungs were the most common sites of recurrence which is in
partial agreement with the results from other studies. Lin
et al. [16] analyzed the sites of distant recurrence in 116
metastatic TNBC patients and reported that the majority of
metastases were in lungs and liver. The brain was the third
most common site of recurrence. However, in recently
published study, TNBC tumors were associated with a
greater risk of brain and lung metastases [14]. In contrast, in
other studies, the rates of local relapse or bone metastases
were the highest [4, 23]. The frequency of liver metastases
in our study was low; this result was consistent with the
observation from a previous study [24]. According to initial
staging in our study, the recurrences were 1 % (1 patient),
36 % (25 patients), and 63 % (44 patients), respectively, for
patients with stages I, II, and III breast cancer. These data
were similar to results described by Alarcon-Rozas et al.
[25] (7.5, 32.5, and 60 %, respectively).
After a 6 year follow-up, DFS and OS in our study were
68 and 62 %, respectively. These results accord with a
previous study which did not include TNBC patients with
stage IV; 5-year DFS and OS were 68.2 and 74.5 %,
respectively [26]. However, in the above-mentioned Kap-
lan et al. [7] study, 5-year relapse-free survival (RFS) and
OS in TNBC patients were 84 and 81 %, respectively. This
result may be dependent on the difference in the staging of
breast cancer between studies—in our study, majority of
patients had more advanced disease (more patients with
stage III and less with stage I), whereas nearly 80 % of
patients in Kaplan study presented with stage I or II.
In a recent retrospective study, TNBC metastatic
patients were divided into two subgroups by RFS [27]. The
analysis showed that patients with RFS C 3 years had
better outcomes—higher disease control rate (DCR),
longer progression-free survival (PFS) to first-line pallia-
tive chemotherapy, and longer OS than those with
RFS \ 3 years (DCR 55 vs. 77 %, p = 0.022; median PFS
3.6 vs. 7.7 months, p = 0.0001; median OS 17.4 vs.
42.0 months, p = 0.0003). In our study, 155 patients
(71 %) had RFS C 3 years. Only 7 patients experienced
recurrence after 3 years from primary diagnosis and 3 of
them died. On the other hand, almost all patients with
RFS \ 3 years passed away (59 of 63 patients).
Furthermore, patients with brain metastases have poor
outcomes. The median survival from brain metastases has
been reported to be between 2.9 and 4.9 months, compared
to 6.3 months in our study [6, 15–18, 28]. Brain metastases
were the first site of recurrence in 19 patients (8.3 %) (in
some of them metastases occurred concurrently in other
sites). None of the patients developed brain metastases at
the diagnosis of breast cancer. On the other hand, in a recent
study, the incidence of brain metastases as the first site of
recurrence in TNBC patients initially at stage I–III was
4.7 % [29]. The incidence of brain metastases as the first
site of relapse in the in the above-mentioned study led by
Park was much more common in patients with shorter RFS
than in those with longer RFS (16 vs. 3 %, p = 0.047) [27].
Similar results were found in our study—in the same group
of patients (metastatic TNBC, initially presented with
stages I–III), brain metastases were more likely to develop
in patients with RFS \ 3 years then with RFS C 3 years
(24 and 3 %, respectively).
The most relevant factor responsible for survival in this
study was tumor size. The hazard ratio (HR) of recurrence
in patients with a tumor [5 cm was 16 times higher than
among patients with a tumor \2 cm. A hazard for death
was also elevated in patients with large tumors (HR = 8.21
in tumors [5 cm). These results were in agreement with a
previous report where the tumor size was the most
important prognostic factor in TNBC patients [5]. Even
small, node-negative (T1N0) TNBC tumors appear to have
a higher recurrence rate, which was documented in some
studies as well [30, 31]. According to these observations,
TNBC patients should be given more aggressive treatment,
Table 4 Factors influencing disease-free survival (DFS) and overall









T4 15.99 3.55–71.95 0.000
T3 16.39 3.53–76.11 0.000









Brain metastases 2.00 1.20–3.33 0.008
Bone metastases 2.13 1.25–3.63 0.005
Liver metastases 2.06 1.01–4.19 0.047





T4 11.56 2.63–50.93 0.001
T3 8.21 1.71–39.29 0.008
T2 4.47 1.05–19.00 0.042
N3 3.95 1.27–12.27 0.018
N2 2.59 1.32–5.09 0.006
N1 1.77 1.03–3.07 0.040
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even if they are in a low-risk category. Apart from tumor
size, the patients’ prognosis in our and other studies
depended also on nodal status [8, 32]. In a recent study,
survival did not differ among patients with N1, N2, and N3
[33]. In contrast, some analysis showed that TNM staging
was not sufficient for predicting therapeutic outcome for
TNBC patients due to the different biology of this breast
cancer subtype [34].
It is known that TNBC affects younger women. How-
ever, one question that should be addressed is whether
younger age is associated with poor prognosis in this group
of patients. The results of studies are ambiguous. Kassam
et al. [35] reported that TNBC patients \50 years had
worse outcome. In other study, age was not related to
prognosis [8]. On the other hand, Ovcaricek et al. [26]
showed that age [65 years was an independent prognostic
factor for DFS and that the risk of recurrence was 1.79-fold
higher in older patients than in younger patients. Interest-
ingly, in the univariate analysis of our study, older patients
had shorter survival (age [ 65 vs. \ 65 years, p = 0.036),
but this result lost its independent prognostic value in the
multivariate analysis. Only 55 % of patients older than
65 years received adjuvant/neoadjuvant chemotherapy
(among stage I–III TNBC), whereas this rate in younger
patients was 91 %. This can explain our founding at least
partially.
To the best of our knowledge, this is the largest study
evaluating TNBC in Poland. Recurrence rates for different
sites were presented by cumulative hazard rates and annual
hazard rates. However, longer time of observation is nec-
essary to complete and verify these results, especially in
terms of recurrence in different sites.
Patients and oncologists always have a dilemma on how
to cope with this aggressive disease. For patients, the
diagnosis of breast cancer is fearsome; so when they know
additionally that they suffer from TNBC—a subtype with
poor outcomes—this situation is often more stressful. We
recommend that this group of patients should be offered to
participate in clinical trials with novel agents.
Conclusions
TNBC patients have a unique pattern of relapse, which
occurs mostly in the first 3 years following diagnosis. The
most common sites of recurrence were brain and lungs.
Tumor size was independent prognostic factor for prog-
nosis, and this feature should be mainly considered in the
management of TNBC patients. This group of patients
should receive aggressive adjuvant therapy to prevent early
recurrence or death. Further prospective clinical trials are
needed to identify the most efficient therapy in order to
improve survival outcomes.
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